Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products. It operates through two segments, Commercial Franchise and Development Portfolio. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It is also developing Cevira, a photodynamic drug-device combination product candidate for the non-surgical treatment of high-grade cervical dysplasia. The company has a license agreement with Asieris MediTech Co to develop and commercialize Cevira; and a strategic agreement with Richard Wolf GmbH to develop and commercialize a 4K LED high-definition reusable blue light cystoscope based on Richard Wolf's System blue technology. It sells its products to pharmaceutical wholesalers, pharmacies, and hospitals through license partners. It has partnership with Artera for digital pathology AI test evaluation for bladder cancer. The company operates in the Nordic countries, Germany, France, Austria, the United Kingdom, the Benelux, Italy, other European countries, Canada, and the United States. Photocure ASA was founded in 1993 and is headquartered in Oslo, Norway.
Frequently asked questions
What sector does Photocure (PHO) operate in?
Photocure belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is Photocure (PHO) current stock price?
As of the latest data, Photocure stock price is NOK 54.00, with a previous close of NOK 53.50. Photocure gained NOK 0.50 in the last trading session, representing a 0.93% increase.
What is Photocure (PHO) current market capitalization?
Photocure market cap is approximately 1.45 billion.
What is Photocure (PHO) Earnings Per Share (EPS)?
The trailing EPS is NOK 2.91, and the forward EPS is NOK 2.59.
What is Photocure (PHO) Price-to-Earnings (P/E) ratio?
Photocure current P/E ratio is 18.56, with a forward P/E of 20.89.
Does Photocure (PHO) pay dividends?
No. Photocure does not pay a dividend.
When is Photocure (PHO) next earnings report?
Photocure is expected to release its next earnings report on September 30, 2026.
What is Photocure (PHO) beta (volatility) score?
Photocure has a beta of 0.343, indicating lower volatility than the overall market.
